Benralizumab
Brand name: Fasenra Pen
Rank #237 of 500 drugs by total cost
$54.8M
Total Cost
9,334
Total Claims
$54.8M
Total Cost
501
Prescribers
$5,871
Cost per Claim
104
Beneficiaries
15,952
30-Day Fills
$109K
Avg Cost/Provider
19
Avg Claims/Provider
About Benralizumab
Benralizumab (sold as Fasenra Pen) was prescribed 9,334 times by 501 Medicare Part D providers in 2023, costing the program $54.8M. At $5,871 per claim, this is a high-cost medication.
Related Drugs by Cost
| # | Drug | Total Cost | Claims |
|---|---|---|---|
| 234 | Allopurinol (Allopurinol) | $56.9M | 3,852,206 |
| 235 | Exenatide Microspheres (Bydureon Bcise) | $56.6M | 48,670 |
| 236 | Valsartan (Valsartan) | $56.4M | 1,481,937 |
| 237 | Benralizumab (Fasenra Pen) | $54.8M | 9,334 |
| 238 | Netarsudil Mesylat/Latanoprost (Rocklatan) | $54.7M | 103,171 |
| 239 | Amifampridine Phosphate (Firdapse) | $54.4M | 1,203 |
| 240 | Dapaglifloz Propaned/Metformin (Xigduo Xr) | $54.4M | 58,629 |
Data from CMS Medicare Part D Prescriber-Drug Public Use File, 2023. Methodology